Market Data 
Markets
Replies to post #228392 on Biotech Values
01/23/20 6:34 PM
NKTR—…you knew CMC issue as major already - which is why our main takeaways from JPM call are different.
01/23/20 7:38 PM
NKTR—I never heard WL in any previous CC…he seemed better than others.
Wei Lin, M.D., joined Nektar in November 2018 as Senior Vice President of Clinical Development and Head of Nektar’s Oncology Programs... Prior to joining Nektar, Dr. Lin served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer at Genentech. During his seven years at Genentech, he held several senior leadership positions of increasing responsibility including Global Clinical Leader of Cancer Immunotherapy in lung and head and neck cancer, where he led a team of 20 medical directors and clinical scientists and directed clinical development strategy for cancer immunotherapy in lung cancer and executed registration trials in lung cancer and head and neck cancer including the successful readouts of five Phase 3 trials in first-line lung cancer and regulatory filing of three of these trials.
…Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals. Dr. Lin received a B.A. in physics from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center.
AI
